Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus CHLOR TRIMETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus CHLOR TRIMETON.
CHILDREN'S ZYRTEC ALLERGY vs CHLOR-TRIMETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral H1 histamine receptors, inhibiting histamine-mediated allergic and inflammatory responses.
Chlorpheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, thereby preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, bronchoconstriction, and sensory nerve stimulation.
5 mg (1 tablet or 5 mL oral solution) once daily; dosing frequency may be increased to 10 mg once daily (2 tablets or 10 mL) for more severe symptoms.
4 mg orally every 4-6 hours, not exceeding 24 mg/day. Also available as 8 mg or 12 mg extended-release tablets once daily at bedtime.
None Documented
None Documented
Terminal half-life 8.5–10.5 hours in children 2–5 years; 9–11 hours in children 6–12 years; 8–9 hours in adults. Clinically, supports once-daily dosing.
Terminal elimination half-life is 12-15 hours in adults, with clinical context: the antihistamine effect persists longer than plasma levels due to active metabolite production and tissue binding.
Primarily renal (60% unchanged) via tubular secretion; 40% metabolized in liver to inactive metabolites excreted in urine; <1% fecal.
Primarily hepatic metabolism (N-dealkylation and oxidative pathways); renal excretion of metabolites accounts for ~70% of elimination, with <1% excreted unchanged in urine. Fecal elimination is negligible (<5%).
Category C
Category C
Antihistamine
Antihistamine